Purple Biotech Ltd. — 2020 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter report; quarterly results are not provided in the filing text. Financial statements are audited and prepared under IFRS, in U.S. dollars.
Business context
Purple Biotech is an Israel-based clinical-stage biotechnology company focused on oncology candidates CM24 and NT219, alongside FDA-approved Consensi, a celecoxib/amlodipine combination for osteoarthritis pain and hypertension. U.S. Consensi sales launched in May 2020 through commercial partners; the company reported limited sales to date. China and South Korea commercialization remains subject to local regulatory approval. The company acquired FameWave, CM24’s former owner, in January 2020 and changed its name from Kitov Pharma to Purple Biotech in December 2020.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $1.0 million | $1.0 million |
| Research and development expense | $7.5 million | $2.7 million |
| SG&A expense | $6.3 million | $6.1 million |
| Operating loss | $12.6 million | $7.2 million |
| Net loss | $28.1 million | $5.9 million |
| Net operating cash used | $12.1 million | $5.6 million |
| Cash and cash equivalents | $11.2 million | $4.4 million |
| Cash, cash equivalents and short- and long-term deposits | $60.9 million | $4.4 million |
| Working capital | $56.2 million | $4.8 million |
| Total assets / liabilities | $83.8 million / $4.1 million | $14.7 million / $3.9 million* |
| Borrowings | None | None reported |
Amounts are rounded. The filing states no material product-sales revenue; reported revenue consisted of Consensi commercialization milestone payments. Profit margins are not meaningful given minimal revenue and ongoing development costs.
Changes and notable items
- Revenue was unchanged year over year, while R&D expense rose 180%, mainly from NT219’s clinical study and CM24 manufacturing and trial preparation. Operating loss increased 76%.
- Net loss rose by $22.2 million, principally because of $15.7 million in warrant-related expense, largely fair-value changes in derivative warrants, and higher R&D costs. The warrant expense was a significant non-cash/valuation-driven item; it should not be read as equivalent to operating cash burn.
- The company raised substantial equity and warrant financing during 2020. Financing activities provided $68.5 million net; operating cash use was $12.1 million. Management said available cash and cash equivalents were sufficient for the next 12 months, while also warning that additional funding may be needed for longer-term development.
- Adjusted operating loss, a non-IFRS measure excluding share-based compensation, was $10.0 million versus $5.9 million in 2019. It is not a substitute for IFRS results.
- Management reported no material capital-expenditure commitments and no material off-balance-sheet arrangements. Contractual obligations totaled $4.2 million, including $2.9 million of purchase obligations.
Outlook, risks and contingencies
- NT219 began a Phase 1/2 study in the second half of 2020, including planned single-agent and cetuximab-combination evaluation. CM24 development is planned with Bristol Myers Squibb: a Phase 1/2 combination study with nivolumab in non-small cell lung cancer and, with nab-paclitaxel, in pancreatic cancer. The filing expected CM24 study initiation in 2021; it gives no financial guidance or revenue forecast.
- The company expects continued losses and substantial development spending. Clinical success, regulatory approval, commercialization, partner performance, payer coverage, manufacturing scale-up, and access to future capital remain uncertain. COVID-19 had slowed clinical and commercial activity and could cause further disruption.
- Consensi faces a generic challenge: Lupin filed an ANDA and alleged certain patents were invalid or not infringed. Purple sued in September 2020; litigation and discovery were scheduled during 2021.
- Bar-Ilan University and BIRAD sued in December 2020, alleging ownership of a TyrNovo patent. Purple said it could not yet assess the likelihood or potential exposure. Israeli shareholder class-action proceedings also remain pending; mediation was anticipated in one case. A separate Israeli securities enforcement arrangement included a NIS 1.5 million company fine, payable in installments. The U.S. securities class actions were settled for $2.0 million, funded by insurers.
- TyrNovo’s IIA-funded technology carries royalty obligations on relevant future sales and restrictions on transferring funded know-how or manufacturing outside Israel. No royalties had been paid as of year-end; the filing cites a maximum grant-based royalty amount of approximately NIS 5.5 million, excluding interest.
- The auditor identified valuation of acquired in-process R&D intangible assets as a critical audit matter. The assets were $20.5 million at year-end; impairment testing depended on estimates including future development costs, revenue, success rates, and discount rates. No impairment was recorded.
Important facts for investors to verify
- Confirm the actual liquidity runway and cash-burn assumptions against the $60.9 million of cash and deposits, $12.1 million operating cash use, and management’s 12-month sufficiency statement.
- Track NT219 and CM24 trial initiation, enrollment, safety, efficacy, timing, and collaboration responsibilities; the filing’s clinical expectations are forward-looking, not results.
- Check Consensi sales, royalties, commercial milestones, and partner performance. Reported 2020 revenue was milestone-based, not evidence of meaningful product-sales uptake.
- Assess the Lupin patent dispute, the Bar-Ilan/BIRAD ownership claim, and remaining shareholder litigation for outcomes, costs, and potential impact on intellectual property or commercialization.
- Review dilution from 2020 share and warrant financings and potential future exercises. The filing’s cover-page share count and financial-statement share data appear to use different share/ADS bases; reconcile them with the 1 ADS-to-10 ordinary-share ratio and the post-period disclosures.
- Evaluate the assumptions supporting the $20.5 million in-process R&D asset valuation and the sensitivity of impairment conclusions to clinical, commercial, and discount-rate changes.